|
ACT Corporate Partner Message
|
|
|
|
Top 3 Mistakes Made During IND Enabling Studies:
How a CRO Can Help You Avoid Them
|
|
Uncover common mistakes during IND enabling studies and learn how preclinical Contract Research Organizations (CROs), like Noble Life Sciences, provide crucial expertise to skillfully sidestep these pitfalls.
|
|
|
|
Mistake #1: Inadequate Toxicology Studies
|
|
Thorough toxicology studies are vital for evaluating safety, mitigating trial risks, and achieving regulatory compliance.
CROs with experienced scientific teams and state-of-the-art facilities can help design protocols that are regulatory compliant, ensuring accurate and reliable data for FDA submission.
|
|
Mistake #2: Inefficient Timeline Management
|
|
Straying too far from timelines can lead to financial losses, missed market opportunities, and delays in delivering therapies to patience.
Partnering with a CRO proficient in project management and IND submission processes can streamline preclinical studies, optimize data collection, and expediate submissions.
|
|
Mistake #3: Underestimating Costs
|
|
Underestimating the true costs of these studies can compromise study scope, regulatory compliance, and data quality.
CROs offer transparent cost estimates, regulatory expertise, access to specialized resources, and optimized study design, helping companies plan better and maintain data integrity.
|
|
|
|
|
|
|